Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 2
Volume: 1
Issue: 2
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Issue: 1
Updates and Advances in Basal Cell Carcinoma
Volume: 2
SABCS 2020: Reflections in HER2+ Breast Cancer
Current and Emerging Trends in Chronic Myeloid Leukemia
My Treatment Approach: Locally Advanced Lung Cancer
Utilizing Tumor Metabolism in Solid Malignancies
Updates in ESR1-Mutant Breast Cancer
My Treatment Approach: Multiple Myeloma
My Treatment Approach: Chronic Lymphocytic Leukemia
Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Role of Trop-2 as an Actionable Biomarker in Solid Tumors
The Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer
ESMO 2020 Congress: Focus in Genitourinary Cancers
Updates and New Targets in NSCLC: An OncLive® Scientific Interchange and Workshop
2020 EBMT Meeting Reporter
Considerations for the Management of Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers
Year in Review: Updates in DLBCL Treatment
Updates in Relapsed/Refractory Metastatic Renal Cell Carcinoma: An OncLive® Scientific Interchange and Workshop
Current and Emerging Treatments in Follicular Lymphoma
Antibody-Drug Conjugates in HER2+ Breast Cancer
New Developments in the Use of Immunotherapy for the Treatment of Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
2020 World GI: Updates in HER2+ GI Cancers
Exploring Therapeutic Strategies in Myelodysplastic Syndromes
Volume: 2020
Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
OncLive® provides updates on the treatment of patients with diffuse large B-cell lymphoma through a Scientific Exchange Workshop.
ASCO 2020: Update on Genitourinary Cancers
Advanced HER2-Expressing Breast Cancer: An OncLive® Scientific Interchange and Workshop
My Treatment Approach: HER2-Positive Breast Cancer
Year in Review: Evolving Landscape in Multiple Myeloma
Therapeutic Changes in HER2+ Breast Cancer
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
